Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Should l Buy CPRX?
Source: Globenewswire
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, which represents a 28% premium over the 30-day volume-weighted average price as of April 22, 2026, indicating strong confidence in Catalyst's future potential.
- Market Entry Strategy: This acquisition marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and providing better treatment options for patients with rare diseases, which is expected to significantly enhance its competitiveness in the North American market.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to integrate Catalyst's product portfolio with its own expertise to develop a next-generation therapeutic platform for rare diseases, further solidifying its position in the global pharmaceutical market.
- Leadership Outlook: Angelini Pharma CEO Sergio Marullo di Condojanni stated that this acquisition is a crucial step in the company's five-year transformation strategy aimed at enhancing patient care quality through innovation and global expansion, driving sustainable long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.860
Low
33.00
Averages
34.00
High
35.00
Current: 30.860
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, which represents a 28% premium over the 30-day volume-weighted average price as of April 22, 2026, indicating strong confidence in Catalyst's future potential.
- Market Entry Strategy: This acquisition marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and providing better treatment options for patients with rare diseases, which is expected to significantly enhance its competitiveness in the North American market.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to integrate Catalyst's product portfolio with its own expertise to develop a next-generation therapeutic platform for rare diseases, further solidifying its position in the global pharmaceutical market.
- Leadership Outlook: Angelini Pharma CEO Sergio Marullo di Condojanni stated that this acquisition is a crucial step in the company's five-year transformation strategy aimed at enhancing patient care quality through innovation and global expansion, driving sustainable long-term growth.
See More
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $31.50 Per Share in $4.1 Billion Transaction
Acquisition Announcement: Catalysts Pharmaceuticals is set to be acquired by Angelini Pharma for $3.50 per share, totaling a deal valued at $4.1 billion.
Market Impact: The acquisition reflects a significant investment in the pharmaceutical sector, highlighting the ongoing consolidation trends within the industry.
See More
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1B
- Acquisition Details: Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, with unanimous board approval from both companies and expected closure in Q3 2026.
- Premium Analysis: The acquisition price represents a 28% premium over Catalyst's 30-day volume-weighted average trading price as of April 22, 2026, indicating Angelini Pharma's recognition of Catalyst's future potential and possibly enhancing its market position in rare diseases.
- Integration Strategy: Following the acquisition, Angelini Pharma plans to integrate Catalyst's portfolio with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases, further expanding its product offerings.
- Financing and Partnerships: The transaction will involve participation from Blackstone funds and select international partners, financed with support from BNP Paribas, reflecting market confidence and backing for the deal.
See More
Catalyst Pharmaceuticals Settles Patent Litigation with Hetero Labs
- Settlement Agreement: Catalyst Pharmaceuticals has reached a settlement with Hetero Labs, allowing Hetero to market a generic version of FIRDAPSE starting January 2035, marking a significant advancement in the company's patent litigation and reducing future legal risks.
- Litigation Termination: The agreement results in the termination of all ongoing patent litigation between Catalyst, SERB, and Hetero regarding FIRDAPSE, avoiding the scheduled trial set for May 18, 2026, and allowing the company to allocate legal resources more effectively towards other strategic objectives.
- Market Access Restrictions: Hetero's ability to launch its generic drug in the U.S. will be restricted, requiring FDA approval before it can enter the market, providing Catalyst with a time advantage to protect its market share in the competitive landscape.
- Industry Impact: Catalyst's previous settlements with multiple pharmaceutical companies demonstrate its strong negotiation capabilities and legal strategies, further solidifying its market position in the rare disease treatment sector.
See More
Angelini Pharma Evaluates Potential Acquisition of Catalyst Pharmaceuticals
- Stock Surge: Catalyst Pharmaceuticals (CPRX) shares soared 19% following reports of a potential acquisition by Angelini Pharma, boosting its market cap to $3.3 billion, indicating strong market optimism regarding new growth opportunities.
- Acquisition Evaluation: Italian drugmaker Angelini Pharma is working with advisers to evaluate a potential purchase of Catalyst, although no deal is guaranteed, highlighting Angelini's strategic intent to expand into external markets.
- Strategic Intent: A representative from Angelini Pharma stated that evaluating growth opportunities is integral to the company's strategy, reflecting its ongoing commitment to enhancing the group's market positioning and ensuring optimal solutions for patients.
- Future Outlook: Catalyst forecasts a revenue growth of 21% to 26% for FIRDAPSE in 2026 while expanding AGAMREE market penetration, demonstrating the company's proactive approach in product promotion and market expansion.
See More
Catalyst Pharmaceuticals Reports Record Revenues and Strong Growth Outlook for 2026
- Significant Revenue Growth: Catalyst Pharmaceuticals reported total revenues of $589 million for 2025, reflecting a 19.8% year-over-year increase that exceeded prior guidance, showcasing the company's strong market performance and strategic execution.
- Outstanding Product Performance: FIRDAPSE achieved net product revenue of $358.4 million, up 17% year-over-year, while AGAMREE saw a remarkable 67.5% increase, indicating an improving market penetration in therapeutic areas.
- Optimistic Future Outlook: Management set 2026 total revenue guidance between $615 million and $645 million, with FIRDAPSE expected to generate $435 million to $450 million, demonstrating confidence in sustained product growth.
- Strengthened Market Strategies: The company is aggressively advancing market penetration for FIRDAPSE and AGAMREE, particularly in idiopathic and cancer-associated LEMS, which is expected to further enhance market share and customer base.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, which represents a 28% premium over the 30-day volume-weighted average price as of April 22, 2026, indicating strong confidence in Catalyst's future potential.
- Market Entry Strategy: This acquisition marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and providing better treatment options for patients with rare diseases, which is expected to significantly enhance its competitiveness in the North American market.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to integrate Catalyst's product portfolio with its own expertise to develop a next-generation therapeutic platform for rare diseases, further solidifying its position in the global pharmaceutical market.
- Leadership Outlook: Angelini Pharma CEO Sergio Marullo di Condojanni stated that this acquisition is a crucial step in the company's five-year transformation strategy aimed at enhancing patient care quality through innovation and global expansion, driving sustainable long-term growth.
See More
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $31.50 Per Share in $4.1 Billion Transaction
Acquisition Announcement: Catalysts Pharmaceuticals is set to be acquired by Angelini Pharma for $3.50 per share, totaling a deal valued at $4.1 billion.
Market Impact: The acquisition reflects a significant investment in the pharmaceutical sector, highlighting the ongoing consolidation trends within the industry.
See More
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1B
- Acquisition Details: Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, with unanimous board approval from both companies and expected closure in Q3 2026.
- Premium Analysis: The acquisition price represents a 28% premium over Catalyst's 30-day volume-weighted average trading price as of April 22, 2026, indicating Angelini Pharma's recognition of Catalyst's future potential and possibly enhancing its market position in rare diseases.
- Integration Strategy: Following the acquisition, Angelini Pharma plans to integrate Catalyst's portfolio with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases, further expanding its product offerings.
- Financing and Partnerships: The transaction will involve participation from Blackstone funds and select international partners, financed with support from BNP Paribas, reflecting market confidence and backing for the deal.
See More
Catalyst Pharmaceuticals Settles Patent Litigation with Hetero Labs
- Settlement Agreement: Catalyst Pharmaceuticals has reached a settlement with Hetero Labs, allowing Hetero to market a generic version of FIRDAPSE starting January 2035, marking a significant advancement in the company's patent litigation and reducing future legal risks.
- Litigation Termination: The agreement results in the termination of all ongoing patent litigation between Catalyst, SERB, and Hetero regarding FIRDAPSE, avoiding the scheduled trial set for May 18, 2026, and allowing the company to allocate legal resources more effectively towards other strategic objectives.
- Market Access Restrictions: Hetero's ability to launch its generic drug in the U.S. will be restricted, requiring FDA approval before it can enter the market, providing Catalyst with a time advantage to protect its market share in the competitive landscape.
- Industry Impact: Catalyst's previous settlements with multiple pharmaceutical companies demonstrate its strong negotiation capabilities and legal strategies, further solidifying its market position in the rare disease treatment sector.
See More
Angelini Pharma Evaluates Potential Acquisition of Catalyst Pharmaceuticals
- Stock Surge: Catalyst Pharmaceuticals (CPRX) shares soared 19% following reports of a potential acquisition by Angelini Pharma, boosting its market cap to $3.3 billion, indicating strong market optimism regarding new growth opportunities.
- Acquisition Evaluation: Italian drugmaker Angelini Pharma is working with advisers to evaluate a potential purchase of Catalyst, although no deal is guaranteed, highlighting Angelini's strategic intent to expand into external markets.
- Strategic Intent: A representative from Angelini Pharma stated that evaluating growth opportunities is integral to the company's strategy, reflecting its ongoing commitment to enhancing the group's market positioning and ensuring optimal solutions for patients.
- Future Outlook: Catalyst forecasts a revenue growth of 21% to 26% for FIRDAPSE in 2026 while expanding AGAMREE market penetration, demonstrating the company's proactive approach in product promotion and market expansion.
See More
Catalyst Pharmaceuticals Reports Record Revenues and Strong Growth Outlook for 2026
- Significant Revenue Growth: Catalyst Pharmaceuticals reported total revenues of $589 million for 2025, reflecting a 19.8% year-over-year increase that exceeded prior guidance, showcasing the company's strong market performance and strategic execution.
- Outstanding Product Performance: FIRDAPSE achieved net product revenue of $358.4 million, up 17% year-over-year, while AGAMREE saw a remarkable 67.5% increase, indicating an improving market penetration in therapeutic areas.
- Optimistic Future Outlook: Management set 2026 total revenue guidance between $615 million and $645 million, with FIRDAPSE expected to generate $435 million to $450 million, demonstrating confidence in sustained product growth.
- Strengthened Market Strategies: The company is aggressively advancing market penetration for FIRDAPSE and AGAMREE, particularly in idiopathic and cancer-associated LEMS, which is expected to further enhance market share and customer base.
See More
